- Home
- LVLU vs XLO Comparison
LVLU vs XLO Comparison
Compare LVLU & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- XLO
- Stock Information
- Founded
- LVLU 1996
- XLO 2016
- Country
- LVLU United States
- XLO United States
- Employees
- LVLU N/A
- XLO N/A
- Industry
- LVLU Catalog/Specialty Distribution
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- XLO Health Care
- Exchange
- LVLU Nasdaq
- XLO Nasdaq
- Market Cap
- LVLU 47.5M
- XLO 37.9M
- IPO Year
- LVLU 2021
- XLO 2021
- Fundamental
- Price
- LVLU $0.94
- XLO $0.66
- Analyst Decision
- LVLU Hold
- XLO Buy
- Analyst Count
- LVLU 3
- XLO 1
- Target Price
- LVLU $1.58
- XLO $4.00
- AVG Volume (30 Days)
- LVLU 30.8K
- XLO 409.2K
- Earning Date
- LVLU 03-05-2025
- XLO 11-07-2024
- Dividend Yield
- LVLU N/A
- XLO N/A
- EPS Growth
- LVLU N/A
- XLO N/A
- EPS
- LVLU N/A
- XLO N/A
- Revenue
- LVLU $324,699,000.00
- XLO $4,620,000.00
- Revenue This Year
- LVLU N/A
- XLO N/A
- Revenue Next Year
- LVLU $1.72
- XLO $368.76
- P/E Ratio
- LVLU N/A
- XLO N/A
- Revenue Growth
- LVLU N/A
- XLO N/A
- 52 Week Low
- LVLU $0.81
- XLO $0.50
- 52 Week High
- LVLU $2.13
- XLO $1.93
- Technical
- Relative Strength Index (RSI)
- LVLU 32.48
- XLO 33.10
- Support Level
- LVLU $0.82
- XLO $0.67
- Resistance Level
- LVLU $0.93
- XLO $1.28
- Average True Range (ATR)
- LVLU 0.07
- XLO 0.10
- MACD
- LVLU -0.00
- XLO -0.03
- Stochastic Oscillator
- LVLU 16.60
- XLO 3.89
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).